Traci Parry

Bio & Education

Dr. Parry is a clinical exercise physiologist, directs the Exercise Oncology Research Laboratory, and is a member of the Cardiac Metabolism Research Laboratory group. Her research aims to understand 1) the underlying physiological and metabolic mechanisms of muscle wasting in chronic disease (cardiovascular disease, cancer, etc.), 2) how physical activity prior to (“pre-habilitation”) and during (rehabilitation) chronic disease supports traditional treatment (pharmacological, etc), and 3) how these exercise interventions alter physiological, psychological, and metabolic biomarkers as well as functional clinical outcomes to reduce fatigue and improve quality of life.

Dr. Parry earned her doctorate from the University of Northern Colorado while conducting research at the UNC Cancer Rehabilitation Institute. Prior to joining UNCG, she was a postdoctoral research fellow at the McAllister Heart Institute within the University of North Carolina, Chapel Hill. Dr. Parry is an ACSM Certified Clinical Exercise Physiologist and is a member of the American College of Sports Medicine, American Heart Association, American Society for Investigative Pathology, and the American Physiological Society.

Courses Taught

• KIN 220 Lifetime Wellness

SELECTED PUBLICATIONS

Parry TL, Mota R, Yates C, Tulasi D, Schisler JC, Patterson C, Zaglia T, Sandri M, Willis MS. Increasing Cardiomyocyte Atrogin-1 Reduce Aging-Associated Fibrosis and Regulates Remodeling In Vivo (In Press) Amer J Pathology. 2018

Parry TL, Hayward R. Exercise protects against cancer cachexia-induced cardiac dysfunction while inhibiting tumor growth (In Press) Med Sci Sport Exer. 2018.

Parry TL, Starnes JW, O’Neal S, Bain JR, Muehlbauer MJ, Honcoop A, Ilaiwy A, Christopher P, Patterson C, Willis MS. Untargeted metabolomics analysis of ischemia-reperfusion-injured hearts ex vivo from sedentary and exercise-trained rats. Metabolomics. 14(8), 2018.

Jensen B, Parry TL, Huang W, Ilaiwy A, Bain J, Newgard C, Muehlbauer M, O’Neal S, Patterson C, Johnson G, Johnson G, Willis MS. Effects of the Kinase Inhibitor Sorafenib on Heart, Muscle, Liver, and Serum Metabolism In Vivo using Non-Targeted Metabolomics Analysis. Brit J Pharm. (In Press) 2017.

Jensen B, Stuhlmiller T, Zawistowski J, Chen X, Hicks S, Huang W, Parry TL, Willis MS, Beak JY, Johnson G. Kinome and transcriptome profiling reveal broad and distinct activities of erlotinib, sunitinib, and sorafenib in the mouse heart and suggest cardiotoxicity from combined STAT and EGFR inhibition. J of Am Heart Association. 6(10), 2017.

Mota R, Rodríguez JE, Bonetto A, O’Connell T, Parry TL, Lockyer P, McCudden CR, Asher S, Couch M, Willis MS. Post-Translationally Modified Muscle-Specific Ubiquitin Ligases as Circulating Biomarkers in Experimental Cancer Cachexia. Am J Cancer Res. 7(9):1948, 2017.

Parry TL, Starnes JW, O’Neal S, Bain JR, Muehlbauer MJ, Honcoop A,Ilaiwy A, Christopher PM, Patterson C, Willis MS. Exercise-induced alterations in skeletal muscle, heart, liver, and serum metabolome identified by non-targeted metabolomics analysis. Metabolites. 7(3), 2017.

Jensen B, Parry TL, Tang W, Ilaiwy A, Bain J, Newgard C, Muehlbauer M, Patterson C, Johnson G, Willis MS. Non-Targeted Metabolomics Analysis of the effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver, and Serum Metabolism In Vivo. Metabolites. 7(3),31, 2017.

Brown DI, Parry TL, Willis MS. The Hand that Feeds: Ubiquitin Ligases and Post-Translational Regulation of Energy in the Heart. Comprehensive Physiology (7): 841-862, 2017.

Parry TL & Willis MS. Regulation of Autophagy by Ubiquitin Ligases: Their Role in Cardiac Metabolism, Cardioprotection and Therapeutic Potential. BBA Mol Basis for Disease 1862(12):2259-2269, 2016.

Parry TL, Hayward R. Exercise training does not affect anthracycline antitumor efficacy while attenuating cardiac dysfunction. Am J Physiol Regul Integr Comp Physiol 309:6, R675-R683, 2015.